China Biologic Products Holdings Inc operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares China Biologic Products Holdings Inc with three other
companies in this sector in China:
Tonghua Dongbao Medicines Company Limited
sales of 2.69 billion Chinese Renmimbi [US$378.65 million]
of which 87%
Hualan Biological Engineering Inc
(3.22 billion Chinese Renmimbi [US$453.20 million]
of which 75%
was Blood Product), and
Beijing Tiantan Biologic.
(2.93 billion Chinese Renmimbi [US$412.93 million]
of which 100%
was Biological products industry).
During the year ended December of 2018, sales at
China Biologic Products Holdings Inc were 3.09 billion Chinese Renmimbi (US$435.50 million).
increase of 23.9%
versus 2017, when the company's sales were 2.49 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at China Biologic Products Holdings Inc
(and since 2013, sales have increased a total of 148%).